MedTrace Logo

Efficacy of Switching to DTG/3TC in Virologically-suppressed Adults Currently on B/F/TAF

NCT04585737 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 222

Last updated 2024-10-17

Study results available
· View outcomes & findings →

Summary

Phase 4, randomized, open-label study to evaluate the efficacy, safety and tolerability of switching virologically suppressed adults living with HIV on bictegravir/tenofovir alafenamide/emtricitabine to dolutegravir/lamivudine

Conditions

  • HIV I Infection

Interventions

DRUG

Dolutegravir / Lamivudine Pill

Experimental

DRUG

Bictegravir / Emtricitabine / Tenofovir Alafenamide Pill

Active comparator

Sponsors & Collaborators

  • ViiV Healthcare

    collaborator INDUSTRY

  • Charlotte-Paige Rolle, MD

    lead OTHER

Principal Investigators

  • Charlotte-Paige Rolle, MD · Orlando Immunology Center

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-10-05
Primary Completion
2023-08-03
Completion
2023-08-10
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04585737 on ClinicalTrials.gov